Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JANUS 2: ruxolitinib plus capecitabine versus placebo plus capecitabine in previously treated advanced pancreatic adenocarcinoma
NL-OMON41730Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Jan 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing Capecitabine + ruxolitinib with Capecitabine + placebo (2 arms). Primary endpoint: Overall survival. Started Jan 2015; status: active, not recruiting.
02
Drugs
ruxolitinibcapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON41730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41730.